What It Is:

ClinOps GPS is Reverba’s clinical engagement model for improving recruitment, retention, and study execution.

The model combines investigator development, site training and engagement, patient recruitment and pre-qualification, and in-trial experience measurement. All programs are delivered through the reverbaBRIDGE platform, enabling coordinated execution and real-time visibility across the trial ecosystem.

Why It Matters:

Recruitment delays, site variability, and participant dissatisfaction slows progress and increases risk. ClinOps GPS helps sponsors address these challenges through a structured engagement model that improves candidate flow, strengthens site responsiveness, and supports a better experience for participants throughout the study. 

How It Works:

ClinOps GPS activates investigators, sites, patients, and advocacy communities through a coordinated engagement model designed to support recruitment, retention, and trial readiness.

Powered by the reverbaBRIDGE platform, these programs connect site engagement, patient outreach, pre-qualification, and trial experience insights to reduce site burden and strengthen participation across the study.

Let’s talk about how ClinOps GPS can accelerate your clinical trials while improving the patient experience.


The Latest

  • Perspective From Patients as Partners: Sustaining Patient Engagement Through Organizational Changes
    Perspective From Patients as Partners: Sustaining Patient Engagement Through Organizational Changes

    At Patients as Partners 2026, CEO Cheryl Lubbert shared how sustaining patient engagement through organizational change requires intentional design, with systems built to hold as teams, priorities, and programs shift.

  • Pharma USA 2026: AI Scales Reach in Pharma. But What Actually Changes Patient and HCP Behavior?
    Pharma USA 2026: AI Scales Reach in Pharma. But What Actually Changes Patient and HCP Behavior?

    AI is becoming a baseline expectation in pharma. At Pharma USA 2026, discussions reflected less focus on whether AI should be used and more on how it is being applied…

  • Approval Is Not the Finish Line: Turning Late-Stage Clinical Evidence Into Real-World Impact
    Approval Is Not the Finish Line: Turning Late-Stage Clinical Evidence Into Real-World Impact

    Late-stage clinical programs establish the evidence required for regulatory evaluation, but they do not guarantee adoption, access, or commercial performance. Translating that evidence into real-world impact requires patient-centered execution and…